SITC Archive Library

SITC 2015 Annual Meeting & Associated Programs: 2015 Biomarkers Debate - Biomarkers in Cancer Immunotherapy: Oasis or Mirage
November 8, 2015
Gaylord National Hotel & Convention Center National Harbor, MD

Program Organizers
Organized in collaboration with the SITC Annual Program Committee and the SITC Industry Committee

Program Summary
From the Society for Immunotherapy of Cancer (SITC), these enduring materials from the 2015 Biomarkers Debate organized in collaboration with the SITC Annual Program Committee and the SITC Industry Committee and presented on Sunday, November 8, 2015 in National Harbor, MD, consist of a point-counterpoint debate surrounding the utility of biomarkers in cancer immunotherapy, complete with audience Question & Answer and extended panel discussion about the future of biomarkers and clinical development. The use of biomarkers to select patients for treatment is becoming increasingly important in cancer treatment, especially as they relate to cancer immunotherapy. However, the biology surrounding biomarkers for cancer immunotherapy is complex, and it is often difficult to take data from clinical outcomes and translate them into practice. Along with multiple PD-L1 diagnostic assays with differing results, these points of contention have led to dilemmas and confusion within the cancer immunotherapy field.

#Biomarkers #ClinicalTrials #Melanoma #Non-SmallCellLungCancer 
#RenalCellCarcinoma #PresentationSlides #AnnualMeeting 
#SITC #Cytokines #Nivolumab #Pembrolizumab #Atezolizumab #Clinician #Industry #Oncologist
#Researcher #2015 #Video